Testing Stored Control-arm Specimens Could Dramatically Increase Statistical Power Yet Reduce Costs in Cancer Screening Trials

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2024 Dec 19

PMID 39699223

Authors

Hormuzd A Katki

Affiliations

Soon will be listed here.

References

Sasieni P . Effect of an Invitation or the Effect of Participation: What Should Randomized Controlled Trials of Cancer Screening Examine?. J Clin Oncol. 2024; 42(28):3266-3269. DOI: 10.1200/JCO.23.01673. View

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C . Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021; 397(10290):2182-2193. PMC: 8192829. DOI: 10.1016/S0140-6736(21)00731-5. View

Hackshaw A, Berg C . An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial. Lancet Oncol. 2021; 22(10):1360-1362. DOI: 10.1016/S1470-2045(21)00204-7. View

Neal R, Johnson P, Clarke C, Hamilton S, Zhang N, Kumar H . Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. Cancers (Basel). 2022; 14(19). PMC: 9564213. DOI: 10.3390/cancers14194818. View

Aberle D, Berg C, Black W, Church T, Fagerstrom R, Galen B . The National Lung Screening Trial: overview and study design. Radiology. 2010; 258(1):243-53. PMC: 3009383. DOI: 10.1148/radiol.10091808. View

Sasieni P, Brentnall A . More efficient, smaller multicancer screening trials. J Natl Cancer Inst. 2024; 117(3):450-455. PMC: 11884843. DOI: 10.1093/jnci/djae251. View

Rubinstein W, Patriotis C, Dickherber A, Han P, Katki H, LeeVan E . Cancer screening with multicancer detection tests: A translational science review. CA Cancer J Clin. 2024; 74(4):368-382. PMC: 11226362. DOI: 10.3322/caac.21833. View

Prorok P, Andriole G, Bresalier R, Buys S, Chia D, Crawford E . Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2001; 21(6 Suppl):273S-309S. DOI: 10.1016/s0197-2456(00)00098-2. View

Katki H, Prorok P, Castle P, Minasian L, Pinsky P . Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening. J Natl Cancer Inst. 2024; 116(10):1675-1682. DOI: 10.1093/jnci/djae218. View

10.

Weiss N . The withholding of test results as a means of assessing the effectiveness of treatment in test-positive persons. J Clin Epidemiol. 2012; 66(4):355-8. DOI: 10.1016/j.jclinepi.2012.07.011. View

11.

Feng X, Zahed H, Onwuka J, Callister M, Johansson M, Etzioni R . Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis. JAMA. 2024; 331(22):1910-1917. PMC: 11000135. DOI: 10.1001/jama.2024.5814. View

12.

Weiss N . Randomized trials of multicancer screening tests: augmenting their ability to identify a genuine mortality benefit. J Natl Cancer Inst. 2024; 116(7):1005-1007. PMC: 11223825. DOI: 10.1093/jnci/djae059. View

13.

Minasian L, Pinsky P, Katki H, Dickherber T, Han P, Harris L . Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. J Natl Cancer Inst. 2022; 115(3):250-257. PMC: 9996206. DOI: 10.1093/jnci/djac218. View